Summary
The goal of this trial is to learn about the antibody acasunlimab (an antibody also known
as GEN1046) when it is used alone and when it is used together with standard of care
treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without
chemotherapy), for treatment of patients with certain types of cancer. All subjects will
receive active drug; no one will receive placebo.
This trial has 2 parts. The purpose of the first part is to find out if acasunlimab is
safe and to find out the best doses of acasunlimab to use. The purpose of the second part
is to give acasunlimab to more subjects to see how well the doses of acasunlimab selected
in the first part work against cancer when given alone and how well they work when given
with pembrolizumab (with or without other chemotherapy) or docetaxel.
Trial details include:
- The average trial duration for an individual subject will be about 74 weeks.
- The average treatment duration for an individual subject will be about 21 weeks.
- The visit frequency will be weekly at first and lessening over time until visits are
only once every 3 weeks.